linjc16/ctgov huggingface dataset:
Universal Screening for Maternal Depression With the CHICA System

Study Overview
=================
Brief Summary
-----------------
The CHICA system is a clinical decision support system that uses adaptive turnaround documents to provide point-of-care information to clinicians. We will be studying whether it can help in the diagnosis and referral of mothers with maternal depression.

Official Title
-----------------
Universal Screening for Maternal Depression With the CHICA System

Conditions
-----------------
Maternal Depression

Intervention / Treatment
-----------------
* Other: CHICA PSF plus JIT
* Other: CHICA maternal depression PSF
* Other: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All families of patients age 0 to 15 months Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PSF-JIT<br>Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis. | Other: CHICA PSF plus JIT<br> <br> |
| Experimental: PSF<br>Mothers in this arm receive screening questions on the prescreener form | Other: CHICA maternal depression PSF<br> <br> |
| Placebo Comparator: Control<br>Mothers in this arm receive no maternal depression CHICA additional care | Other: Control<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of mothers screening positive for maternal depression. |  | 1 year after child's birth | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of mothers diagnosed with maternal depression |  | one year after child's birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
maternal depression, clinical decision support
Longitudinal Study of Cell Free DNA in Lung Transplant

Study Overview
=================
Brief Summary
-----------------
Lung transplant is a viable treatment strategy for many with end-stage lung diseases. Despite advances in both the surgical and medical management, lung transplant recipients experience episodes of allograft insult and injury that lead to dysfunction and ultimately contribute to graft failure. The primary noninvasive tool for monitoring the lung allograft, pulmonary function testing, is neither sensitive nor specific for lung allograft injury which makes the management of lung transplant recipients particularly challenging. A decline in pulmonary function tests prompts invasive procedures such as bronchoscopy with transbronchial lung biopsy to diagnose the cause of allograft injury, although this, too, is not 100% sensitive, and oftentimes patients are treated empirically for rejection when no other etiology for lung function decline is identified. Empiric treatment prompted by extrapulmonary drivers of decline in lung function may result in inappropriate exposure to risks of augmented immunosuppression. The purpose of this study is to determine to what extent monitoring of donor-derived cell free DNA in lung transplant recipients can be used as a marker of lung injury and stability.

Official Title
-----------------
A Longitudinal Study of Donor-Derived Cell Free DNA in Lung Transplant

Conditions
-----------------
Lung Transplant Rejection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 years old Actively listed or have recently had a double lung transplant Participant is willing and able to provide informed consent Exclusion Criteria: Prior organ transplantation Transplantation performed in the setting of hospitalization for acute illness or decompensation Unable or unwilling to consent for enrolment Single lung transplant recipient Consideration for multi-organ transplantation Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Consented adult lung transplant recipients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship | Determine the relationship between donor derived cell free DNA and lung allograft function during the first year after lung transplant. | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative Assessments | Quantitative assessments of dd-cfDNA obtained at pre-specified timepoints post-transplant compared to clinical events (PGD scores, detection of allograft dysfunction, rejection, or infection). | 12 Months |
The Relationship Between Cerebral State and Emotion in Anesthesiologist and Surgeon

Study Overview
=================
Brief Summary
-----------------
This study was designed to observe the cerebral state obtained via wavelet analysis (HXD-I,Beijing Easymonitor Technology Co.Ltd, China) and evaluate the emotion in various states in anesthesiologist and surgeon. And we also explore the association between the characteristic of cerebral state and the emotion.

Detailed Description
-----------------
A total of 20 anesthesiologist (A group) and 20 surgeon(S group) in Ruijin hospital were enrolled for this study. Except had a medical history of mental illness or emotional disorder and pregnant woman. A group and S group completed emotional self-perceived questionnaire and then observe the characteristic of cerebral state via cerebral state monitor. They also completed anonymous questionnaire, including Maslach Burnout Inventory-General Survey(MBI-GS), Self-reporting Inventory-90(SCI-90), Burnout Measure(BM).

Official Title
-----------------
Department of Anesthesiology, Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Conditions
-----------------
Burnout, Professional

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A total of 20 anesthesiologist (A group) and 20 surgeon(S group) in Ruijin hospital were enrolled for this study. Exclusion Criteria: had a medical history of mental illness or emotional disorder and pregnant woman.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship between cerebral state and emotion in doctors | subjects completed emotional self-perceived questionnaire and then observe the characteristic of cerebral state via cerebral state monitor. They also completed anonymous questionnaire. | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anaesthetists, surgeons, stress, burnout
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

Study Overview
=================
Brief Summary
-----------------
Parkinson Disease is one of the most common neurodegenerative illnesses. First degree relatives of Parkinson patient are in high risk for developing the disease. We will try to detect early changes in brain metabolism before the appearance of Parkinson symptoms. Participants: first degree relatives of diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes. The examination results will be given to the participants by a doctor from the neurology department.

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy first degree relatives of diagnosed Parkinson patients Exclusion Criteria: patients unable to understand and sign an informed consent minors people with psychiatric disorders or a history of major head trauma

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson, fdg pet-ct, i123 dat scan, first degree relatives of diagnosed Parkinson patients, with no clinical evidence of movement disorders
Ventricular Arrhythmias After Pulmonary Vein Isolation

Study Overview
=================
Brief Summary
-----------------
The investigators study aimed to observe the occurrence of new premature ventricular complexes and other ventricular arrhythmias after pulmonary vein isolation.

Detailed Description
-----------------
Atrial fibrillation is the most common arrhythmia with a lifetime risk for development of over 20%. Pulmonary vein isolation is now established as therapy of choice for patients with symptomatic atrial fibrillation. It is well known that this interventional therapy inevitably modulates the intracardiac autonomic nervous system. While this ablation might alter atrial electrophysiology beneficially, the impact on ventricular electrophysiology remains unclear.

Official Title
-----------------
A Single-center Observational Study to Examine the Occurrence of Ventricular Arrhythmias After Pulmonary Vein Isolation

Conditions
-----------------
Ventricular Arrhythmias, Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Paroxysmal atrial fibrillation scheduled to undergo pulmonary vein isolation Exclusion Criteria: Age < 18 years Persistent atrial fibrillation Life expectancy less than 12 months Acute myocardial infarction, coronary artery bypass graft surgery, open heart surgery, or percutaneous transluminal coronary angioplasty within less than 3 months prior to inclusion Documentation of >30 premature ventricular complexes per hour, salvos or ventricular tachycardias prior to atrial fibrillation ablation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventricular arrhythmias | Number of patients with premature ventricular complexes, ventricular tachycardias or ventricular fibrillation. | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arrhythmia recurrence | Number of patients with premature ventricular complexes, ventricular tachycardias or ventricular fibrillation. | one year |
Evaluation of Echinacea for the Common Cold

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether three Echinacea preparations with different chemical compositions are effective for prevention or treatment of the common cold.

Detailed Description
-----------------
Echinacea is a widely used herbal remedy for the common cold. Previous clinical trials designed to assess the efficacy of Echinacea for prevention or treatment of the common cold have produced inconsistent results. A variety of different Echinacea products have been used in these clinical trials. Recent studies indicate that different Echinacea preparations have dramatically different phytochemical profiles. The available clinical trial data provide no information about the potential role of the different constituents of Echinacea in common cold prevention or treatment. Our hypothesis is that the variation in reported clinical effectiveness may be due to differences in the phytochemical profile of the Echinacea preparations used. This study will address the following specific aims: 1) Evaluate the effectiveness of chemically defined extracts of E. angustifolia root which contain alkamides, echinacoside or polysaccharidelglycoprotein for common cold prevention or treatment; 2) Assess the correlation between specific Echinacea metabolites in serum and nasal secretions and efficacy for prevention and treatment of colds; and 3) Determine the effect of different Echinacea preparations on the host response to rhinovirus infection.

Official Title
-----------------
Evaluation of Echinacea in a Human Rhinovirus Challenge

Conditions
-----------------
Common Cold

Intervention / Treatment
-----------------
* Drug: Echinacea


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Echinacea|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
common cold, Echinacea
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study

Study Overview
=================
Brief Summary
-----------------
safety, efficacy and acceptability of Flavocoxid

Detailed Description
-----------------
Safety, Efficacy and acceptability of Flavocoxid (Limbrel) compared with Naproxen in Subjects with Osteoarthritis of the Knee. A Pilot Study

Official Title
-----------------
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel) Compared With Naproxen in Subjects With Osteoarthritis of the Knee. A Pilot Study

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Dietary Supplement: flavocoxid
* Drug: Naproxen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OA of the knee,K-L grade 2-3 in general good health is currently taking an NSAID or COX-2 inhibitor - Exclusion Criteria: pregant or nursing women grade 1 or 4 OA any significant medical condition that in the opinion of the physician might put the subject at risk in this study any form of arthropathy other than OA any condition that might confound the evaluation of the pain, stiffness or function of the target joint intra-articular cotticosteroid inkection in the target joint within 3 month of the screening visit concomitant use of other anti-inflammatory or anti arthritic medication or products(including OTC and herbal preparations) Low dose aspirin for cardio-protection is allowed concomitant use of coumadin or other anticoagulant or anti-platelet medication concomitant use of gastro-protectiv medications including, but not limited to, H2 blockers and proton pump inhibitors, including OTC and herbal products History of allergy to Flavonoids -

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: flavocoxid<br>medical food | Dietary Supplement: flavocoxid<br>* flavonoid mixture<br>* Other names: Limbrel;|
| Active Comparator: naproxen<br>NSAID | Drug: Naproxen<br>* non-steroidal anti-inflammatory drug<br>* Other names: naprosyn;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compare efficacy |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate safety |  |  |
A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Study Overview
=================
Brief Summary
-----------------
This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS IVA disease over time.

Official Title
-----------------
A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)

Conditions
-----------------
MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written, signed informed consent, or in the case of subjects age < 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures. Documented history of reduced GALNS activity relative to the normal range of the laboratory performing the assay, or documented result of molecular genetic testing confirming diagnosis of MPS IVA. Willing and able to comply with all study procedures. Exclusion Criteria: Use of any investigational product or investigational medical device within 30 days prior to screening. Previous hematopoietic stem cell transplant (HSCT). Concurrent disease or condition that would interfere with study participation or pose a safety concern.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MPS IVA<br>Subjects with mucopolysaccharidosis IVA (Morquio Syndrome) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endurance |  | Study Visit | 
| Respiratory Function |  | Study Visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mucopolysaccharidosis IV type A, MPS IV Type A, Mucopolysaccharidosis IVA, MPS IVA, Morquio A Syndrome, Lysosomal Storage Disorder, LSD, N-acetylgalactosamine-6-sulfatase, galactose-6-sulfatase, GALNS, enzyme replacement therapy, ERT
The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if the source of dietary protein (pork or chicken/fish) as a part of the DASH diet affects blood pressure control in adults with high blood pressure.

Detailed Description
-----------------
High blood pressure is a major risk factor for heart disease and stroke and affects 50 million people in the United States. Making healthy food choices, such as those in the DASH (Dietary Approaches to Stop Hypertension) Diet, has been shown to improve blood pressure control in people with high blood pressure. The purpose of this study is to determine if the source of dietary protein (pork or chicken/fish) as a part of the DASH diet affects blood pressure control in adults with high blood pressure.

Official Title
-----------------
The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults (S31)

Conditions
-----------------
Hypertension, Dyslipidemias

Intervention / Treatment
-----------------
* Behavioral: DASH diet counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female age 40-75 BMI 25-40 kg/m2 systolic blood pressure 120-160 mm Hg diastolic blood pressure <100 mm Hg non-diabetic, no acute illness not following vigorous exercise program urinary continence Exclusion Criteria: age <40 or >75 BMI <25 or >40 kg/m2 systolic blood pressure <120 or >160 mm Hg diastolic blood pressure >100 mm Hg diabetic, acute illness following vigorous exercise program urinary incontinence current smoker

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Dietary Counseling<br>Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure | Behavioral: DASH diet counseling<br>* Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in blood pressure |  | After 6 weeks of following DASH diet | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in blood lipids |  | After 6 weeks of following DASH diet |